VARILRIX LIVE ATTENUATED CHICKENPOX VACCINE 10^3.3 PFU / 0.5ml powder + solvent for injection medication leaflet

J07BK01 • live attenuated chickenpox vaccine • Antiinfectives for systemic use | Viral vaccines | Varicella zoster vaccines

The live attenuated varicella vaccine is used to prevent chickenpox, a highly contagious viral disease caused by the varicella-zoster virus (VZV). The vaccine contains a weakened form of the virus, which stimulates the immune system to produce antibodies against VZV, providing long-term protection against infection.

The vaccine is administered subcutaneously, usually in two doses, with the first dose given at 12-15 months of age and the second between 4 and 6 years. It is recommended for both children and adults who have not had chickenpox or been previously vaccinated.

Common side effects include redness, pain, or swelling at the injection site, mild fever, and rashes. In rare cases, severe allergic reactions or neurological complications may occur.

The live attenuated varicella vaccine is an effective preventive measure, helping to reduce the incidence of chickenpox and its associated complications, such as secondary bacterial infections and viral pneumonia.